🫁 Asthma Therapeutic Vaccine Tracker Dashboard

Updated July 2026. This page tracks therapeutic biologics — there is no true "asthma vaccine" in clinical development. The severe asthma biologic landscape remains dominated by five FDA-approved products: omalizumab (anti-IgE, Xolair), mepolizumab (anti-IL-5, Nucala), benralizumab (anti-IL-5R, Fasenra), dupilumab (anti-IL-4Rα, Dupixent), and tezepelumab (anti-TSLP, Tezspire). Recent developments: depemokimab (long-acting anti-IL-5, GSK) — FDA under review with positive Phase 3 SWIFT-1/SWIFT-2 trials; itepekimab (anti-IL-33, Regeneron/Sanofi) — Phase 3 AERIFY trials.

Comprehensive tracking of asthma therapeutic vaccine development including biologics (anti-IgE, anti-IL-5, anti-IL-4/13, anti-TSLP), allergen immunotherapy for allergic asthma, and novel disease-modifying approaches. Asthma affects 25 million US adults (8%), 262 million globally with 262,000 deaths annually. Chronic inflammatory airway disease causing wheezing, shortness of breath, chest tightness. Immunotherapy and biologics target underlying immune dysregulation - IgE-mediated Type 2 inflammation, eosinophilic pathways, Th2 cytokines. Multiple FDA-approved biologics revolutionizing severe asthma management. Allergen immunotherapy prevents asthma development in allergic rhinitis patients. Next-generation vaccines targeting airway remodeling, epithelial dysfunction. Complementary to inhaled corticosteroids and bronchodilators. Disease-modifying potential with monitoring tools.

āš ļø MAJOR GLOBAL HEALTH BURDEN:

Asthma affects 25 million US adults (8%), 262 million globally. Leading chronic disease in children - 6 million US kids affected. 262,000 deaths annually worldwide (mostly preventable with proper treatment). 1.6 million ER visits/year US, 439,000 hospitalizations, 3,600 deaths. Disproportionately affects minorities and low-income communities (environmental exposures, access barriers). $81.9 billion annual US costs ($50.3B direct medical, $31.6B lost productivity). Quality of life severely impaired - missed school/work (13.8M days/year), sleep disruption, exercise limitation, psychological burden (anxiety about attacks). Current medications (inhalers, steroids) control symptoms but don't modify disease. Biologics offer disease modification for severe asthma. Immunotherapy prevents asthma in at-risk patients - true prevention strategy.

Asthma Immunotherapy by Development Phase